Effect of Casodex on Tumour Hypoxia - Prostate Cancer

University Health Network, Toronto

Status: Completed

Conditions: Prostatic Neoplasms

Treatments: Procedure: hypoxia measurement

Study type: Interventional

Funder types: Other; NETWORK

Identifiers

NCT00188708

National Cancer Inst of Canada

UHN REB 00-0430-C

Details and patient eligibility

About

Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.

Enrollment: 30 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men with histologically proven prostatic carcinoma, stage cT2, N0, M0, receiving neoadjuvant bicalutamide plus conformal radiotherapy in study 9907, who have previously participated in the prostate cancer hypoxia project
• informed consent

Exclusion criteria

• Coagulopathy

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

hypoxia measurement

Experimental group

Description:

Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy

Treatment:

Procedure: hypoxia measurement